Generic Oncology Drugs Market report projects revenue to surpass US$ 41.5 Bn by 2031-end

Generic Oncology Drugs Market 2022

The global Generic Oncology Drugs Market is expected to reach US$ 41.5 Bn by the year 2031 at a CAGR of 6%. Healthcare systems have been basically emphasizing on affordability as well as quality of the medical services. However, now, digitization has come through, which would drive revolution in the same healthcare vertical. The life sciences would go digitally innovative. This would be the way healthcare vertical would go in the next 10 years.

Sales revenue from generic oncology drugs in 2020 was US$ 23 Bn, which is expected to surge to US$ 41.5 Bn by the end of 2031. Analysts at Persistence Market Research have also predicted the market to rise at a healthy CAGR of 6% over the next ten years.

Instances of cancer cases have risen exponentially across the globe. From diagnosis to treatment, all aspects of the disease are being researched extensively by numerous market players. Oncology treatment and drugs have proven to be very expensive for everyone, and this has been affecting overall treatment of cancer globally.

Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/25480

Research is focusing on developing new and cost-effective generic oncology drugs that would be helpful in treatment of types of cancers. A major trend to watch out for over the decade would be the use of nanotechnology in the development of generic oncology drugs. With cancer rates surging, the need for a diverse portfolio of generic drugs is being realized, and major as well as new market players are investing in developing a vast portfolio that caters to most needs of patients suffering from different cancer conditions.

Prime players in the industry are investing in the research & development of new products, which, in turn, is expanding their product portfolios across various cancer types.

In September 2021, MSN Labs, a pharmaceutical firm based in India, announced the launch of its new generic drug that will be used in treatment of renal cancer. The drug is called Cabolong, which is a branded generic of Cabozantinib. The drug will be available for treatment in three strength factors of 20mg, 40mg, and 60mg.

In February 2021, Glenmark Pharma, a renowned name in the pharmaceutical industry announced the launch of a new generic cancer drug for the treatment of kidney cancer. This drug is the generic version of FDA approved Suntinib and is named SUTIB.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/25480

Company Profiles:

Novartis AG
Pfizer Inc.
GlaxoSmithKline plc
CELGENE CORPORATION
Teva Pharmaceutical Industries Ltd.
Merck & Company, Inc
Aurobindo Pharma.
Hikma Pharmaceuticals PLC
Mylan N.V.
NATCO Pharma Limited.
Others.

Key Takeaways from Market Study

The global generic oncology drugs market is predicted to expand at a CAGR of 6% through 2031.
Generic oncology drugs revenue is anticipated to top US$ 41.5 Bn by the end of the decade.

The South Asia market is predicted to rise at the fastest CAGR over the decade.
In 2020, global market revenue totaled a net worth of US$ 23 Bn.

Increasing incidence of cancer across the globe, growing focus on healthcare, rising healthcare expenditure, and advancements in treatment technologies and drugs are some of the major factors influencing industry growth.

"Key players are focusing on diversifying their product portfolios in order to fulfil high demand for generic oncology drugs," says a Persistence Market Research analyst.

More Valuable Insights on Offer

Persistence Market Research, a research and consulting firm, has published a new market research report on the global generic oncology drugs market that contains industry analysis of 2016-2020 and opportunity assessment for 2021-2031.

The report provides in-depth analysis of the market through different segments, namely, molecule type, by route of administration, by distribution channel, and region. The report also provides supply and demand trends along with an overview of the parent market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/25480

Report Highlights:

Detailed overview of parent market
Changing market dynamics of the industry
In-depth market segmentation
Historical, current and projected market size in terms of value
Recent industry trends and developments
Competitive landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance
Must-have information for market players to sustain and enhance their market footprint

Access Related Reports-

3D Cell Cultures Market - https://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp

The global 3D cell culture market reached a value of around US$ 586.1 Mn in 2014, which is expected to spike up to US$ 2,717.6 Mn by 2020 end.

Health Caregiving Market- https://www.persistencemarketresearch.com/market-research/health-caregiving-market.asp

Global health caregiving market was pegged at more than US $ 70 Bn in 2015 & is estimated to cross US $ 200 bn by the end of 2024, registering a CAGR of 12.6%.

Contact us:

Persistence Market Research          
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About us: 

PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.

This release was published on openPR.